Boehringer Ingelheim and Enara Bio join forces to develop new Cancer Immunotherapies
Boehringer Ingelheim and Enara Bio reported that they have entered into a strategic partnership and licensing agreement to study and
Read more
Oncology
FDA approves Roche’s Xofluza for Influenza post-exposure prophylaxis
Roche has announced that the U.S. FDA has granted supplemental New Drug Application (sNDA) approval for Xofluza, the first single-dose
Read more
EC approves GSK’s Zejula for advanced ovarian cancer treatment
Zejula (niraparib), developed by pharma giant GSK, has become the first polymerase (PARP) inhibitor approved as monotherapy in the EU for
Read more
Phenomic AI starts with $6M using AI/ML for Targeting the Tumor Stroma
Phenomic AI, a Canadian biotechnology company that uses an AI/ML platform for targeting the tumor stroma, has launched with $6
Read more
FDA approves Roche’s Venclexta combos for acute myeloid leukaemia
Roche revealed on Monday that Venclexta ® (venetoclax) in conjunction with azacitidine or decitabine or low-dose cytarabine (LDAC) has been
Read more
HPAPI and ADC manufacturing facility, Merck KGaA, Wisconsin, USA
Darmstadt headquartered Merck KGaA, a leading science and technology company operating in the U.S. & Canada as MilliporeSigma, has announced a
Read more
FDA clears Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for GIST
Deciphera Pharmaceuticals, Inc. has revealed that QINLOCK™ (ripretinib) was formally authorised by the U.S. Food and Drug Administration (FDA) for
Read more
FDA approves Lynparza as maintenance treatment with bevacizumab for HRD-positive ovarian cancer
AstraZeneca and Merck & Co have received the FDA’s approval for Lynparza (olaparib) as 1st-line maintenance treatment with bevacizumab for
Read more
Inovio Pharmaceuticals Stock up 16.36% as HPV drug shows promise
Inovio Pharmaceuticals stock soared by +16.36% on Friday, as HPV drug VGX-3100 showed promise in Phase 2 Trial. Shares of
Read more
Paris-Saclay Research Institute, Servier Group
The Servier Group has commenced the construction of its ultra-modern Research Institute in the Paris-Saclay cluster in France. Covering approximately 45,000 m2,
Read more